DUBLIN – A newly published analysis from Germany's main health technology assessment agency, the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), concluded that the benefit assessment process Germany introduced for new drugs in 2011 has narrowed the information gap on new medicines and provided a fuller understanding of their benefits and risks than that available from other regulatory and academic sources.